BioStock: Mendus in strong position for clinical progress

Q2 brought key milestones to immuno-oncology company Mendus. Preclinical as well as clinical results related to cancer relapse vaccine DCP-001 have set the company up for  potential significant advancements in the clinic in the coming months. Additionally, a strengthened management team and a corporate rebranding also came in Q2, suggestive of a company with a renewed confidence in its aim to bring better treatments to cancer patients. BioStock reached out to Mendus’s CEO Erik Manting to get his thoughts on the past quarter and what lies ahead for the company.

Read the interview with Erik Manting at biostock.se:

https://www.biostock.se/en/2022/09/mendus-valpositionerade-for-kliniska-framsteg/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/